Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20118747 | 0.87 | MME (0.36) | MMETSHRALDH1A1 | |
| SCHEMBL24279501 | 0.86 | MME (0.32) | MME | |
| SCHEMBL4461827 | 0.80 | MAPT (0.41) | MMEALDH1A1 | |
| SCHEMBL23385520 | 0.78 | MME (0.35) | MME | |
| SCHEMBL19413434 | 0.78 | MME (0.30) | MME | |
| SCHEMBL24574924 | 0.78 | TSHR (0.35) | MMETSHR | |
| SCHEMBL21966919 | 0.77 | MME (0.35) | MME | |
| SCHEMBL19403535 | 0.77 | MME (0.32) | MMEALDH1A1 | |
| SCHEMBL2610579 | 0.75 | TSHR (0.33) | MMETSHR | |
| SCHEMBL21152368 | 0.74 | ALDH1A1 (0.37) | MMEALDH1A1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10751346-B2 | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates | MEDIMMUNE LIMITED (GB) | 2020-08-25 | — | — | US | disclosed |
| US-10695433-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2020-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695433-B2 | Pyrrolobenzodiazepine-antibody conjugates | IL2RA, CD4, IL2 | MME 3276/4885TSHR 870/4885ALDH1A1 2032/4885 |
| US-10751346-B2 | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates | PSMA2, PSMA7, FOLH1 | MME 902/4885TSHR 2052/4885ALDH1A1 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.